The condition of patients and the variations of skin lesions should be monitored.[32] It is not necessary to stop using TNF-α-antagonists in patients with mild psoriasis who have not yet significantly impacted normal quality of life.[33,34] On the whole, local application of steroids is the preferred treatment for most lesions.[17,35]. This evidence concerns the gene TNF and psoriasis.